Patents Assigned to Scripps Research Institute
-
Patent number: 12329992Abstract: This disclosure relates to antibodies and antigen binding fragments that specifically bind Ebola virus particles. In certain embodiments, the antibodies and fragments are capable of treating or preventing an Ebola viral infection. In certain embodiments, the antibodies and antigen binding fragments are also contemplated for diagnostic methods and compositions related thereto.Type: GrantFiled: June 9, 2023Date of Patent: June 17, 2025Assignees: Emory University, The Scripps Research InstituteInventors: Rafi Ahmed, Carl Davis, Erica Ollmann Saphire
-
Patent number: 12312396Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: GrantFiled: June 5, 2024Date of Patent: May 27, 2025Assignees: Theraclone Sciences, Inc., International AIDS Vaccine Initiative, Inc., The Scripps Research Institute.Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
-
Patent number: 12281137Abstract: Provided herein are analogs of unnatural nucleotides bearing predominantly hydrophobic nucleobase analogs that form unnatural base pairs during DNA polymerase-mediated replication of DNA or RNA polymerase-mediated transcription of RNA. In this manner, the unnatural nucleobases can be introduced in a site-specific way into oligonucleotides (single or double stranded DNA or RNA), where they can provide for site-specific cleavage, or can provide a reactive linker than can undergo functionalization with a cargo-bearing reagent by means of reaction with a primary amino group or by means of click chemistry with an alkyne group of the unnatural nucleobase linker.Type: GrantFiled: February 22, 2023Date of Patent: April 22, 2025Assignee: The Scripps Research InstituteInventors: Floyd E. Romesberg, Denis A. Malyshev, Lingjun Li, Thomas Lavergne, Zhengtao Li
-
Patent number: 12281142Abstract: The present disclosure relates to recombinant HIV Env polypeptides and their use in the treatment and prevention of HIV/AIDS.Type: GrantFiled: June 1, 2021Date of Patent: April 22, 2025Assignees: International AIDS Vaccine Initiative, Inc., The Scripps Research InstituteInventors: Jon M. Steichen, William R. Schief
-
Patent number: 12269869Abstract: The present disclosure provides compositions, methods, kits, and platforms for selectively activating and deactivating chimeric receptor effector cells using humanized chimeric receptor effector cell switches that comprise a humanized targeting moiety that binds CD19 on a target cell and a chimeric receptor interacting domain that binds to a chimeric receptor effector cell and/or chimeric receptor effector cell switches comprising optimized chimeric receptor interacting domains. Also disclosed are methods of treating disease and conditions with such chimeric receptor effector cells and chimeric receptor effector cell switches.Type: GrantFiled: August 30, 2021Date of Patent: April 8, 2025Assignee: The Scripps Research InstituteInventors: Travis S. Young, Leonard Presta, David Rodgers, Eric Hampton, Timothy Wright, Peter G. Schultz, Eduardo Laborda, Elvira Khialeeva, Sophie Viaud
-
Patent number: 12263165Abstract: The present disclosure provides compounds, their pharmaceutical compositions, and methods of their use for treating mesenchymally-derived or mesenchymally-transformed cancers, such as breast cancers and sarcomas, and for treating diseases or disorders that are characterized by the expression of vimentin.Type: GrantFiled: July 11, 2023Date of Patent: April 1, 2025Assignees: The Scripps Research Institute, Board of Regents, The University of Texas SystemInventors: Luke L. Lairson, Michael J. Bollong, Peter G. Schultz, Sendurai A. Mani
-
Patent number: 12241081Abstract: Methods and systems are described herein for generating engineered B cells with modified immunoglobulin genes. The modified immunoglobulin genes encode modified immunoglobulins that can have high affinity for antigens, including antigens that are variable such the types of antigens on various pathogens that can escape mammalian immune responses.Type: GrantFiled: August 3, 2018Date of Patent: March 4, 2025Assignee: The Scripps Research InstituteInventors: James Even Voss, Raiees Andrabi, Dennis R. Burton, Deli Huang, Alicia Gonzalez-Martin
-
Publication number: 20250051828Abstract: Methods and systems to functionally ablate 3? end of RNA are described. The functional ablation renders polymerases unable to initiate reverse transcription in the absence of an annealing primer. The methods and systems can be used to enhance the specificity and selectivity of cDNA generation from RNA.Type: ApplicationFiled: December 9, 2022Publication date: February 13, 2025Applicants: Seattle Children’s Hospital d/b/a Seattle Children’s Research Institute, The Scripps Research InstituteInventors: Christian Matias Gallardo Garcia Freire, Bruce E. Torbett
-
Patent number: 12209284Abstract: By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and/or interstitial fibrosis and tubular atrophy CAN/IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and/or subtyping of CAN/IFTA.Type: GrantFiled: May 25, 2023Date of Patent: January 28, 2025Assignee: The Scripps Research InstituteInventors: Daniel R. Salomon, Sunil M. Kurian, Steven R. Head
-
Patent number: 12195762Abstract: The slow kinetics and low efficiency of reprogramming methods to generate human induced pluripotent stem cells (iPSCs) impose major limitations on their utility in biomedical applications. Here we describe a chemical approach that dramatically improves (>200 fold) the efficiency of iPSC generation from human fibroblasts, within seven days of treatment. This will provide a basis for developing safer, more efficient, non-viral methods for reprogramming human somatic cells.Type: GrantFiled: May 14, 2021Date of Patent: January 14, 2025Assignee: The Scripps Research InstituteInventors: Tongxiang Lin, Sheng Ding
-
Patent number: 12173291Abstract: Disclosed herein are methods, cells, engineered microorganisms, and kits for increasing the production of polypeptides comprising one or more unnatural amino acids. Further provided are cells, engineered microorganisms, and kits for increasing the retention of unnatural nucleic acids encoding the unnatural amino acids in an engineered cell, or semi-synthetic organism.Type: GrantFiled: June 26, 2020Date of Patent: December 24, 2024Assignee: The Scripps Research InstituteInventors: Floyd E. Romesberg, Michael P. Ledbetter, Rebekah J. Karadeema
-
Patent number: 12109261Abstract: The present invention provides novel engineered influenza hemagglutinin (HA) proteins, related polynucleotide sequences, and vaccine compositions including nanoparticle compositions. Relative to a wildtype HA protein, the engineered HA proteins are stabilized via substitutions of one or more conserved residues in the HA2 ectodomain with hydrophobic residues. The invention also provides methods of using such vaccine compositions in various therapeutic applications, e.g., for preventing or treating influenza viral infections.Type: GrantFiled: May 22, 2024Date of Patent: October 8, 2024Assignee: The Scripps Research InstituteInventors: Linling He, Jiang Zhu, Ian A. Wilson, Yi-Zong Lee
-
Patent number: 12077558Abstract: The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.Type: GrantFiled: February 10, 2023Date of Patent: September 3, 2024Assignees: Bristol-Myers Squibb Company, The Scripps Research InstituteInventors: Michael Anthony Schmidt, Bin Zheng, Kyle Knouse, Justine deGruyter, Martin D. Eastgate, Phil Baran, William R. Ewing, Richard E. Olson, Ivar M. McDonald
-
Patent number: 12018067Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.Type: GrantFiled: January 6, 2023Date of Patent: June 25, 2024Assignees: International AIDS Vaccine Initiative, Inc., The Scripps Research Institute, Theraclone Sciences, Inc.Inventors: Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos, Stephen Kaminsky
-
Publication number: 20240191301Abstract: Described herein are methods, compositions, and systems useful for detecting transplant rejection and associated abnormal conditions in solid organ transplant recipients, such as kidney transplant recipients. Methods described herein may involve combined assessment of blood gene expression profiles from an assessment of particular, related mRNA transcript levels and donor-derived cell-free nucleic acids (dd-cfDNA).Type: ApplicationFiled: January 26, 2024Publication date: June 13, 2024Applicants: Northwestern University, Transplant Genomics, Inc., The Scripps Research InstituteInventors: John Friedewald, Michael M. Abecassis, Rohita Sinha, Sook Hyeon Park, Lihui Zhao, Juston Weems, Sunil M. Kurian, Steve Kleiboeker
-
Patent number: 11998602Abstract: This invention provides novel methods for treating or ameliorating symptoms of demyelinating diseases such as multiple sclerosis. The methods involve administering to subjects in need of treatment a pharmaceutical composition that contains a therapeutically effective amount of taurine and also a compound that induces oligodendrocyte precursor cell (OPC) differentiation (e.g., T3, benztropine, clemastine or miconazole). Some of the methods additionally involve administration to the subject a known agent for treating demyelinating diseases (e.g., SIP receptor agonists) or a known disease modifying drug. The invention also provides methods for increasing myelination and methods for promoting OPC differentiation into oligodendrocytes. These methods entail contacting a population of OPCs with a combination of taurine and a known OPC differentiation-inducing agent such as T3, clemastine, benztropine or miconazole.Type: GrantFiled: November 13, 2018Date of Patent: June 4, 2024Assignee: The Scripps Research InstituteInventors: Luke Lairson, Brittney Beyer, Mingliang Fang, Gary Siuzdak
-
Publication number: 20240158403Abstract: The present disclosure provides novel heteroaryl compounds of formula (IX). Such compounds are useful for the treatment of cancers.Type: ApplicationFiled: January 24, 2024Publication date: May 16, 2024Applicants: Dana-Farber Cancer Institute, Inc., The Scripps Research InstituteInventors: Nathanael S. GRAY, Jianming ZHANG, Barun OKRAM, Xianming DENG, Jae Won CHANG, Amy WOJCIECHOWSKI
-
Patent number: 11970525Abstract: The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family ?-receptor 4 (GFR?4).Type: GrantFiled: October 23, 2020Date of Patent: April 30, 2024Assignees: The Trustees of the University of Pennsylvania, Novartis AG, The Scripps Research InstituteInventors: Donald L. Siegel, Michael C. Milone, Vijay Bhoj, Christoph Rader
-
Patent number: 11964010Abstract: Coronavirus S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the coronavirus S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to coronavirus in a subject. In additional embodiments, the therapeutically effective amount of the coronavirus S ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing coronavirus infection.Type: GrantFiled: March 8, 2021Date of Patent: April 23, 2024Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Scripps Research Institute, Trustees of Dartmouth CollegeInventors: Barney Graham, Jason Mclellan, Andrew Ward, Robert Kirchdoerfer, Christopher Cottrell, Michael Gordon Joyce, Masaru Kanekiyo, Nianshuang Wang, Jesper Pallesen, Hadi Yassine, Hannah Turner, Kizzmekia Corbett
-
Patent number: RE50268Abstract: The present invention relates to an exceptionally broad and potent neutralizing antibody which may comprise cross-clade neutralizing coverage of 83% at a median IC50 of 0.003 ?g/ml, compositions containing the same and uses thereof.Type: GrantFiled: April 8, 2022Date of Patent: January 14, 2025Assignees: International AIDS Vaccine Initiative, The Scripps Research Institute, Cornell UniversityInventors: Dennis R. Burton, Marit J. Van Gils, Wayne Koff, Pascal R. G. Poignard, Rogier W. Sanders, Melissa D. J. S. Simek-Lemos, Devin Sok